146 results on '"Sellner L"'
Search Results
2. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
3. Dissection of CD20 regulation in lymphoma using RNAi
4. Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
5. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT
6. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
7. Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton
8. What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
9. Changes in the treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from a large German claims database
10. Erratum: GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
11. Segmental isodisomy and skewed X-inactivation resulting in haemophilia B in a female
12. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma : A survey of the EBMT lymphoma working party
13. THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
14. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
15. Aggressives B-Zell-Non-Hodgkin-Lymphom der Mamma bei einer 77-jährigen Patientin
16. A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma.
17. Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2
18. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data
19. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
20. DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS
21. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
22. The B cell reseptor signaling output in Burkitt´s lymphoma is genotype specific and impacts sensitivity towards BCR signaling inhibitors
23. T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells
24. SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS
25. 535: Small RNA sequencing identifies microRNAs involved in B-cell receptor signaling in chronic lymphocytic leukemia
26. 827: Ex vivo combinatorial screen to identify drug sensitivity and rational treatment of chronic lymphocytic leukemia
27. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
28. Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton
29. Der frühe expressive Wortschatzumfang simultan mehrsprachig aufwachsender Kinder - ein diagnostisch relevantes Kriterium?
30. What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
31. Aggressives B-Zell-Non-Hodgkin-Lymphom der Mamma bei einer 77-jährigen Patientin.
32. New techniques for evaluating lung immunology and immunopathology
33. HIGH-DOSE PREPARATION WITH THIOTEPA/ETOPOSIDE/ARA-C/MELPHALAN (TEAM) VS BEAM FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN LYMPHOMA: A RETROSPECTIVE STUDY FROM THE EBMT
34. Sensitive detection of Ross River virus - a one-tube nested RT-PCR
35. A one-tube, one manipulation RT-PCR reaction for detection of Ross River virus
36. Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma.
37. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.
38. HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.
39. Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers.
40. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
41. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
42. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia.
43. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
44. An Endoplasmic Reticulum Specific Pro-amplifier of Reactive Oxygen Species in Cancer Cells.
45. Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.
46. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
47. Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells.
48. T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging!
49. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
50. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.